WO2006105338A3 - Fc VARIANTS WITH OPTIMIZED PROPERTIES - Google Patents
Fc VARIANTS WITH OPTIMIZED PROPERTIES Download PDFInfo
- Publication number
- WO2006105338A3 WO2006105338A3 PCT/US2006/011752 US2006011752W WO2006105338A3 WO 2006105338 A3 WO2006105338 A3 WO 2006105338A3 US 2006011752 W US2006011752 W US 2006011752W WO 2006105338 A3 WO2006105338 A3 WO 2006105338A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- variants
- optimized properties
- optimized
- properties
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002602663A CA2602663A1 (en) | 2005-03-31 | 2006-03-31 | Fc variants with optimized properties |
JP2008504389A JP2008537941A (en) | 2005-03-31 | 2006-03-31 | Fc variants with optimized properties |
EP06748967A EP1871808A2 (en) | 2005-03-31 | 2006-03-31 | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
AU2006230413A AU2006230413B8 (en) | 2005-03-31 | 2006-03-31 | Fc variants with optimized properties |
IL186145A IL186145A0 (en) | 2005-03-31 | 2007-09-20 | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66719705P | 2005-03-31 | 2005-03-31 | |
US60/667,197 | 2005-03-31 | ||
US11/124,620 US8188231B2 (en) | 2002-09-27 | 2005-05-05 | Optimized FC variants |
US11/124,620 | 2005-05-05 | ||
US70537805P | 2005-08-03 | 2005-08-03 | |
US60/705,378 | 2005-08-03 | ||
US72329405P | 2005-10-03 | 2005-10-03 | |
US72333505P | 2005-10-03 | 2005-10-03 | |
US60/723,335 | 2005-10-03 | ||
US60/723,294 | 2005-10-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006105338A2 WO2006105338A2 (en) | 2006-10-05 |
WO2006105338A3 true WO2006105338A3 (en) | 2007-03-29 |
Family
ID=37054149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/011752 WO2006105338A2 (en) | 2005-03-31 | 2006-03-31 | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1871808A2 (en) |
AU (1) | AU2006230413B8 (en) |
CA (1) | CA2602663A1 (en) |
IL (1) | IL186145A0 (en) |
WO (1) | WO2006105338A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US8158760B2 (en) | 2000-10-06 | 2012-04-17 | Kyowa Hakko Kirin Co., Ltd | Glycoengineered, recombinant antibody |
US8852586B2 (en) | 2004-11-12 | 2014-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US11851476B2 (en) | 2011-10-31 | 2023-12-26 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
US11932685B2 (en) | 2020-10-23 | 2024-03-19 | Xencor, Inc. | Fc variants with altered binding to FcRn |
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2568898T3 (en) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedure to control the activity of an immunofunctional molecule |
US20070122406A1 (en) * | 2005-07-08 | 2007-05-31 | Xencor, Inc. | Optimized proteins that target Ep-CAM |
AR045563A1 (en) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | ANTIBODIES DIRECTED TO M-CSF |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
CA2565961A1 (en) * | 2004-07-15 | 2006-02-23 | Xencor, Inc. | Optimized fc variants |
BR122018016031B8 (en) | 2004-08-04 | 2021-07-27 | Applied Molecular Evolution Inc | process for producing a variant monoclonal antibody with enhanced adcc response |
EP1931709B1 (en) * | 2005-10-03 | 2016-12-07 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
EP3345616A1 (en) | 2006-03-31 | 2018-07-11 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
CN101479381B (en) | 2006-03-31 | 2015-04-29 | 中外制药株式会社 | Method for control of blood kinetics of antibody |
KR101528939B1 (en) | 2006-07-18 | 2015-06-15 | 사노피 | Antagonist antibody against epha2 for the treatment of cancer |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
WO2008121160A2 (en) * | 2006-11-21 | 2008-10-09 | Xencor, Inc. | Optimized antibodies that target cd5 |
AR063975A1 (en) | 2006-11-28 | 2009-03-04 | Centelion | FC FUSIONS WITH RECEIVER FOR FGF SOLUBLE MODIFIED WITH IMPROVED BIOLOGICAL ACTIVITY |
WO2008091798A2 (en) * | 2007-01-22 | 2008-07-31 | Xencor, Inc. | Optimized ca9 antibodies and methods of using the same |
EP2125893A2 (en) * | 2007-01-23 | 2009-12-02 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
EP2119780B1 (en) * | 2007-01-24 | 2015-03-25 | Kyowa Hakko Kirin Co., Ltd. | Genetically recombinant antibody composition having enhanced effector activity |
WO2008092117A2 (en) * | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
WO2008098115A2 (en) * | 2007-02-07 | 2008-08-14 | Xencor, Inc. | Optimized igf-1r antibodies and methods of using the same |
JP2010526868A (en) | 2007-05-14 | 2010-08-05 | ノビミューン エスアー | Fc receptor binding polypeptide having altered effector function |
EP3392273A1 (en) | 2007-05-30 | 2018-10-24 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
EA201000053A1 (en) * | 2007-08-01 | 2010-08-30 | Глаксо Груп Лимитед | NEW ANTIBODIES |
CN106519025B (en) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | Method for changing isoelectric point of antibody by using amino acid substitution of CDR |
UA121453C2 (en) | 2008-04-11 | 2020-06-10 | Чугей Сейяку Кабусікі Кайся | METHOD OF PREPARATION OF PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY |
US8314213B2 (en) | 2008-04-18 | 2012-11-20 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
US8455249B2 (en) | 2009-05-01 | 2013-06-04 | The University Of Tokyo | Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
AR078470A1 (en) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | ANTIBODIES THAT SPECIFICALLY JOIN THE EPHA2 RECEIVER |
US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
CA2789629A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc. | Cd20 antibodies and uses thereof |
US8975376B2 (en) | 2010-02-23 | 2015-03-10 | Sanofi | Anti-alpha2 integrin antibodies and their uses |
JP5820800B2 (en) | 2010-03-02 | 2015-11-24 | 協和発酵キリン株式会社 | Modified antibody composition |
TWI667346B (en) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | Antibodies with modified affinity to fcrn that promote antigen clearance |
CN103080130B (en) | 2010-05-27 | 2016-08-17 | 默沙东公司 | Preparation has the method for the antibody improving characteristic |
UY33578A (en) | 2010-08-31 | 2012-03-30 | Sanofi Sa | PEPTIDE PEPTIDE OR COMPLEX THAT JOINS INTEGRINE TO (ALPHA) AND METHODS AND USES THAT INVOLVE THE SAME |
WO2012032080A1 (en) | 2010-09-07 | 2012-03-15 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Stabilised human fc |
RU2013115927A (en) | 2010-09-10 | 2014-10-20 | Апексиджен, Инк. | ANTIBODIES AGAINST IL-1β AND METHODS OF APPLICATION |
TWI685503B (en) | 2010-11-30 | 2020-02-21 | 中外製藥股份有限公司 | Cell injury-inducing therapeutic agent |
SG10201509790YA (en) | 2010-11-30 | 2015-12-30 | Chugai Pharmaceutical Co Ltd | Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly |
CN103492565B (en) | 2011-02-25 | 2021-01-29 | 中外制药株式会社 | Fc gamma RIIb specific Fc antibodies |
EP2681243B1 (en) | 2011-03-03 | 2018-09-05 | Apexigen, Inc. | Anti-il-6 receptor antibodies and methods of use |
JP5832559B2 (en) | 2011-03-10 | 2015-12-16 | オメロス コーポレーション | Generation of anti-FN14 monoclonal antibodies by accelerated antibody evolution ex vivo |
EP2698431B1 (en) | 2011-03-30 | 2020-09-09 | Chugai Seiyaku Kabushiki Kaisha | Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity |
US8778345B2 (en) | 2011-04-29 | 2014-07-15 | Apexigen, Inc. | Anti-CD40 antibodies |
EP3392274A1 (en) | 2011-08-12 | 2018-10-24 | Omeros Corporation | Anti-fzd10 monoclonal antibodies and methods for their use |
UY34317A (en) | 2011-09-12 | 2013-02-28 | Genzyme Corp | T cell antireceptor antibody (alpha) / ß |
TW201326209A (en) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
KR20200096692A (en) | 2011-09-30 | 2020-08-12 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecule for promoting elimination of antigens |
EP2762493B1 (en) | 2011-09-30 | 2021-06-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
CN110627902A (en) | 2011-09-30 | 2019-12-31 | 中外制药株式会社 | Antigen binding molecules that induce an immune response against a target antigen |
BR112014007353B1 (en) | 2011-09-30 | 2022-09-13 | Chugai Seiyaku Kabushiki Kaisha | LIBRARY OF ION CONCENTRATION DEPENDENT ANTIBODIES |
BR112014010774A2 (en) | 2011-11-02 | 2017-06-13 | Apexigen Inc | anti-kdr antibodies and methods of use |
KR20210074395A (en) | 2011-11-30 | 2021-06-21 | 추가이 세이야쿠 가부시키가이샤 | Drug containing carrier into cell for forming immune complex |
WO2013087789A1 (en) * | 2011-12-13 | 2013-06-20 | Glykos Finland Ltd. | Antibody isoform arrays and methods thereof |
EP3539982A3 (en) | 2011-12-23 | 2020-01-15 | Pfizer Inc | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
TWI593705B (en) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
AU2013223087B2 (en) | 2012-02-24 | 2018-02-22 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via FcgammaRIIb |
EP2832856A4 (en) | 2012-03-29 | 2016-01-27 | Chugai Pharmaceutical Co Ltd | Anti-lamp5 antibody and utilization thereof |
ES2856272T3 (en) | 2012-05-30 | 2021-09-27 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule to remove aggregated antigens |
KR20220092644A (en) | 2012-05-30 | 2022-07-01 | 추가이 세이야쿠 가부시키가이샤 | Target-tissue-specific antigen-binding molecule |
WO2014030728A1 (en) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | Fcγriib-specific fc region variant |
JP6774164B2 (en) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | Mouse FcγRII specific Fc antibody |
US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
RS57910B1 (en) | 2012-09-27 | 2019-01-31 | Merus Nv | Bispecific igg antibodies as t cell engagers |
US9676861B2 (en) | 2012-10-30 | 2017-06-13 | Apexigen, Inc. | Anti-CD40 antibodies and methods of use |
RU2015115956A (en) | 2012-11-09 | 2017-01-10 | Пфайзер Инк. | ANTIBODIES SPECIFIC TO THE THROMBOCYTE B GROWTH FACTOR, AND THEIR COMPOSITION AND APPLICATION |
EP3557260B1 (en) | 2012-12-21 | 2022-05-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
TWI693073B (en) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | Therapeutic agent for GPC3 target is the effective therapeutic agent for GPC3 target administered to patients |
KR20220103204A (en) | 2013-03-11 | 2022-07-21 | 젠자임 코포레이션 | Hyperglycosylated binding polypeptides |
BR112015024587B1 (en) | 2013-04-02 | 2022-11-29 | Chugai Seiyaku Kabushiki Kaisha | HUMAN IGG1 FC REGION VARIANT, POLYPEPTIDE COMPRISING IT, ITS PRODUCTION METHOD AND PHARMACEUTICAL COMPOSITION |
ES2736326T3 (en) | 2013-05-31 | 2019-12-27 | Zymeworks Inc | Heteromultimers with reduced or silenced effector function |
CN105517571A (en) | 2013-06-24 | 2016-04-20 | 中外制药株式会社 | Therapeutic agent comprising humanized anti-epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma |
PT3050896T (en) | 2013-09-27 | 2021-08-24 | Chugai Pharmaceutical Co Ltd | Method for producing polypeptide heteromultimer |
SG10201810298VA (en) | 2013-11-13 | 2018-12-28 | Pfizer | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
EP3068892A4 (en) | 2013-11-13 | 2017-05-31 | Zymeworks Inc. | Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof |
EP3074424A4 (en) | 2013-11-27 | 2017-06-14 | Zymeworks Inc. | Bispecific antigen-binding constructs targeting her2 |
TWI702316B (en) | 2013-12-04 | 2020-08-21 | 日商中外製藥股份有限公司 | Antigen-binding molecules and their database that change antigen-binding ability in response to compound concentration |
WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
FI3129067T3 (en) | 2014-03-19 | 2023-04-04 | Genzyme Corp | Site-specific glycoengineering of targeting moieties |
CN106459206A (en) | 2014-04-07 | 2017-02-22 | 中外制药株式会社 | Immunoactivating antigen-binding molecule |
KR102409014B1 (en) | 2014-05-08 | 2022-06-14 | 추가이 세이야쿠 가부시키가이샤 | Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective |
MX2016014434A (en) | 2014-05-13 | 2017-02-23 | Chugai Pharmaceutical Co Ltd | T cell-redirected antigen-binding molecule for cells having immunosuppression function. |
MA40764A (en) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
EP3799887A1 (en) | 2014-10-09 | 2021-04-07 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
MA41294A (en) | 2014-12-19 | 2017-11-08 | Chugai Pharmaceutical Co Ltd | ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING FC REGION VARIANTS, AND METHODS OF USE |
KR102605798B1 (en) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
AR104368A1 (en) | 2015-04-03 | 2017-07-19 | Lilly Co Eli | ANTI-CD20- / ANTI-BAFF BIESPECTIFIC ANTIBODIES |
CN107709355B (en) | 2015-05-04 | 2021-09-14 | 阿珀吉尼科斯股份公司 | Single-chain CD40 receptor agonist proteins |
MX2018000344A (en) | 2015-07-10 | 2018-03-14 | Merus Nv | Human cd3 binding antibody. |
CA3025896A1 (en) | 2015-07-23 | 2017-01-26 | The Regents Of The University Of California | Antibodies to coagulation factor xia and uses thereof |
CN108271372B (en) | 2015-09-18 | 2021-07-09 | 中外制药株式会社 | IL-8-binding antibodies and uses thereof |
JP7030689B2 (en) | 2015-10-23 | 2022-03-07 | ファイザー インコーポレイティッド | Anti-IL-2 antibody and its composition and use |
US11660340B2 (en) | 2015-11-18 | 2023-05-30 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function |
EP3378488A4 (en) | 2015-11-18 | 2019-10-30 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
JP7141336B2 (en) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | Anti-myostatin antibodies and methods of use |
CN108368166B (en) | 2015-12-28 | 2023-03-28 | 中外制药株式会社 | Method for improving purification efficiency of polypeptide containing FC region |
AU2017233658B2 (en) | 2016-03-14 | 2023-09-21 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
AU2017235097B2 (en) | 2016-03-15 | 2023-08-31 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies |
MA45328A (en) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF |
CA3026880A1 (en) | 2016-06-08 | 2017-12-14 | Paul Foster | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
WO2018045379A1 (en) | 2016-09-02 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
AU2017331277A1 (en) * | 2016-09-23 | 2019-03-28 | Marengo Therapeutics, Inc. | Multispecific antibody molecules comprising lambda and kappa light chains |
TW201825515A (en) | 2017-01-04 | 2018-07-16 | 美商伊繆諾金公司 | Met antibodies and immunoconjugates and uses thereof |
AU2018244574A1 (en) * | 2017-03-28 | 2019-10-31 | Lyvgen Biopharma Holdings Limited | Therapeutic agents and methods for enhancing immune responses in tumor microenvironment |
KR20230066126A (en) | 2017-07-27 | 2023-05-12 | 알렉시온 파마슈티칼스, 인코포레이티드 | High concentration anti-c5 antibody formulations |
WO2019059411A1 (en) | 2017-09-20 | 2019-03-28 | Chugai Seiyaku Kabushiki Kaisha | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent |
CA3069238A1 (en) * | 2017-11-02 | 2019-05-09 | Systimmune, Inc. | Bispecific antibodies and methods of making and using thereof |
AU2018393076A1 (en) | 2017-12-19 | 2020-07-02 | Surrozen Operating, Inc. | Anti-LRP5/6 antibodies and methods of use |
CN111727203A (en) | 2017-12-19 | 2020-09-29 | 瑟罗泽恩公司 | WNT surrogate molecules and uses thereof |
WO2019143837A1 (en) | 2018-01-17 | 2019-07-25 | Apexigen, Inc. | Anti-pd-l1 antibodies and methods of use |
MX2020009469A (en) | 2018-03-13 | 2021-01-29 | Zymeworks Inc | Anti-her2 biparatopic antibody-drug conjugates and methods of use. |
US11891432B2 (en) | 2018-03-15 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use |
KR20210029158A (en) | 2018-06-03 | 2021-03-15 | 람카프 바이오 베타 엘티디. | Bispecific antibodies to CEACAM5 and CD47 |
TW202016144A (en) | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | Compositions including cd3 antigen binding fragments and uses thereof |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
EP3943108A4 (en) | 2019-03-19 | 2023-01-04 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain |
TW202102544A (en) * | 2019-04-04 | 2021-01-16 | 日商小野藥品工業股份有限公司 | Bispecific antibody |
EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
PE20221661A1 (en) | 2019-12-18 | 2022-10-26 | Hoffmann La Roche | BISPECIFIC ANTI-CCL2 ANTIBODIES |
GB2595299B (en) * | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
CA3193210A1 (en) | 2020-12-18 | 2022-06-23 | Vanessa BUATOIS | Bispecific antibodies against ceacam5 and cd47 |
KR20240021859A (en) | 2021-06-18 | 2024-02-19 | 에프. 호프만-라 로슈 아게 | Bispecific anti-CCL2 antibody |
WO2023242351A1 (en) | 2022-06-16 | 2023-12-21 | Lamkap Bio Beta Ag | Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3 |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999051642A1 (en) * | 1998-04-02 | 1999-10-14 | Genentech, Inc. | Antibody variants and fragments thereof |
WO2000042072A2 (en) * | 1999-01-15 | 2000-07-20 | Genentech, Inc. | Polypeptide variants with altered effector function |
US20020004587A1 (en) * | 2000-04-11 | 2002-01-10 | Genentech, Inc. | Multivalent antibodies and uses therefor |
WO2004029207A2 (en) * | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
WO2004063351A2 (en) * | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
WO2004099249A2 (en) * | 2003-05-02 | 2004-11-18 | Xencor, Inc. | Optimized fc variants and methods for their generation |
WO2005056759A2 (en) * | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
WO2005056606A2 (en) * | 2003-12-03 | 2005-06-23 | Xencor, Inc | Optimized antibodies that target the epidermal growth factor receptor |
WO2005070963A1 (en) * | 2004-01-12 | 2005-08-04 | Applied Molecular Evolution, Inc | Fc region variants |
WO2005092925A2 (en) * | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
WO2006019447A1 (en) * | 2004-07-15 | 2006-02-23 | Xencor, Inc. | Optimized fc variants |
WO2006047350A2 (en) * | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
WO2006053301A2 (en) * | 2004-11-12 | 2006-05-18 | Xencor, Inc. | Fc variants with altered binding to fcrn |
WO2006085967A2 (en) * | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
-
2006
- 2006-03-31 CA CA002602663A patent/CA2602663A1/en not_active Abandoned
- 2006-03-31 WO PCT/US2006/011752 patent/WO2006105338A2/en active Application Filing
- 2006-03-31 EP EP06748967A patent/EP1871808A2/en not_active Withdrawn
- 2006-03-31 AU AU2006230413A patent/AU2006230413B8/en not_active Ceased
-
2007
- 2007-09-20 IL IL186145A patent/IL186145A0/en unknown
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999051642A1 (en) * | 1998-04-02 | 1999-10-14 | Genentech, Inc. | Antibody variants and fragments thereof |
WO2000042072A2 (en) * | 1999-01-15 | 2000-07-20 | Genentech, Inc. | Polypeptide variants with altered effector function |
US20020004587A1 (en) * | 2000-04-11 | 2002-01-10 | Genentech, Inc. | Multivalent antibodies and uses therefor |
WO2004029207A2 (en) * | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
WO2004063351A2 (en) * | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
WO2004099249A2 (en) * | 2003-05-02 | 2004-11-18 | Xencor, Inc. | Optimized fc variants and methods for their generation |
WO2005056606A2 (en) * | 2003-12-03 | 2005-06-23 | Xencor, Inc | Optimized antibodies that target the epidermal growth factor receptor |
WO2005056759A2 (en) * | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
WO2005070963A1 (en) * | 2004-01-12 | 2005-08-04 | Applied Molecular Evolution, Inc | Fc region variants |
WO2005092925A2 (en) * | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
WO2006085967A2 (en) * | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
WO2006019447A1 (en) * | 2004-07-15 | 2006-02-23 | Xencor, Inc. | Optimized fc variants |
WO2006047350A2 (en) * | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
WO2006053301A2 (en) * | 2004-11-12 | 2006-05-18 | Xencor, Inc. | Fc variants with altered binding to fcrn |
Non-Patent Citations (4)
Title |
---|
BLOOD, vol. 104, no. 11, Part 1, November 2004 (2004-11-01), 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 394A, ISSN: 0006-4971 * |
CHAPPEL M S ET AL: "Identification of a secondary FcyRI binding site within a genetically engineered human IgG antibody", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 268, no. 33, 1993, pages 25124 - 25131, XP002337952, ISSN: 0021-9258 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2004 (2004-11-01), LAZAR GREG ET AL: "Improving the efficacy of rituxan by rational protein engineering.", XP002403709, Database accession no. PREV200510269378 * |
LAZAR GREG A ET AL: "Engineered antibody Fc variants with enhanced effector function", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 103, no. 11, March 2006 (2006-03-01), pages 4005 - 4010, XP002403708, ISSN: 0027-8424 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8158760B2 (en) | 2000-10-06 | 2012-04-17 | Kyowa Hakko Kirin Co., Ltd | Glycoengineered, recombinant antibody |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US8852586B2 (en) | 2004-11-12 | 2014-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8883973B2 (en) | 2004-11-12 | 2014-11-11 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US11851476B2 (en) | 2011-10-31 | 2023-12-26 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
US11932685B2 (en) | 2020-10-23 | 2024-03-19 | Xencor, Inc. | Fc variants with altered binding to FcRn |
Also Published As
Publication number | Publication date |
---|---|
WO2006105338A2 (en) | 2006-10-05 |
AU2006230413B8 (en) | 2011-01-20 |
AU2006230413B2 (en) | 2010-09-23 |
EP1871808A2 (en) | 2008-01-02 |
CA2602663A1 (en) | 2006-10-05 |
IL186145A0 (en) | 2008-01-20 |
AU2006230413A1 (en) | 2006-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006105338A3 (en) | Fc VARIANTS WITH OPTIMIZED PROPERTIES | |
WO2007041635A3 (en) | Fc variants with optimized fc receptor binding properties | |
WO2006105062A3 (en) | Altered antibody fc regions and uses thereof | |
WO2007014930A3 (en) | Polyammonium/polysiloxane copolymers | |
WO2004099249A3 (en) | Optimized fc variants and methods for their generation | |
WO2009070243A3 (en) | Wise binding antibodies and epitopes | |
EG25348A (en) | Process for the manufacture of diesel range hydrocarbons. | |
WO2009039307A3 (en) | Hydrogels and methods for producing and using the same | |
WO2007133290A3 (en) | Anti-ox40l antibodies and methods using same | |
WO2007130697A8 (en) | Anti-ephb4 antibodies and methods using same | |
WO2007060117A3 (en) | Chimeric keratin-binding effector proteins | |
PL2468732T3 (en) | 1H-Quinazoline-2,4-diones | |
WO2007112279A3 (en) | Resonators | |
WO2007057018A3 (en) | Glucoamylase variants | |
WO2007127506A8 (en) | Anti-ephrinb2 antibodies and methods using same | |
WO2007056083A3 (en) | Biosynthetic polypeptide fusion inhibitors | |
ZA200500854B (en) | Wine making system. | |
EP1929207A4 (en) | Multi-mode lighter | |
WO2007002096A3 (en) | Methods and compositions for targeting ifnar2 | |
WO2007127830A3 (en) | Dep2 and its uses in major depressive disorder and other related disorders | |
AU2005901102A0 (en) | The I.D. charm | |
AU2006906675A0 (en) | The multiscooper. | |
AU2005906280A0 (en) | Budgetchoice.com | |
AU2005900030A0 (en) | Glowbal, Glowves, Moonstik | |
GB0512422D0 (en) | New polypeptide, uses thereof and methods employing it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2006748967 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1452/MUMNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 186145 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006230413 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2602663 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2008504389 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006230413 Country of ref document: AU Date of ref document: 20060330 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |